title: 2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist.
authors.affiliation: Merck Research Laboratories, Rahway, New Jersey 07065, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Hale
authors.forename: S G
authors.initials: SG
authors.lastname: Mills
authors.forename: M
authors.initials: M
authors.lastname: MacCoss
authors.forename: S K
authors.initials: SK
authors.lastname: Shah
authors.forename: H
authors.initials: H
authors.lastname: Qi
authors.forename: D J
authors.initials: DJ
authors.lastname: Mathre
authors.forename: M A
authors.initials: MA
authors.lastname: Cascieri
authors.forename: S
authors.initials: S
authors.lastname: Sadowski
authors.forename: C D
authors.initials: CD
authors.lastname: Strader
authors.forename: D E
authors.initials: DE
authors.lastname: MacIntyre
authors.forename: J M
authors.initials: JM
authors.lastname: Metzger
mesh_terms: D000284:Administration, Oral; D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D064729:Neurokinin-1 Receptor Antagonists
chemical_list: C099406:L 742694; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists